- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 796046, 12 pages
MHC Universal Cells Survive in an Allogeneic Environment after Incompatible Transplantation
1Institute for Transfusion Medicine, Hannover Medical School, Lower Saxony, 30625 Hannover, Germany
2Institute for Laboratory Animal Science, Hannover Medical School, Lower Saxony, 30625 Hannover, Germany
3Institute for Transfusion Medicine, University Hospital Essen, 45147 Essen, Nordrhein-Westfalen, Germany
4German Red Cross, Blood Services NSTOB, Institute Springe, Lower Saxony, 31832 Springe, Germany
Received 10 June 2013; Revised 29 August 2013; Accepted 29 August 2013
Academic Editor: Chung-Liang Chien
Copyright © 2013 Constança Figueiredo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reduction in any medium, provided the original work is properly cited.
- G. Orlando, P. Baptista, M. Birchall et al., “Regenerative medicine as applied to solid organ transplantation: current status and future challenges,” Transplant International, vol. 24, no. 3, pp. 223–232, 2011.
- A. S. Boyd and P. J. Fairchild, “Approaches for immunological tolerance induction to stem cell-derived cell replacement therapies,” Expert Review of Clinical Immunology, vol. 6, no. 3, pp. 435–448, 2010.
- I. Park, N. Arora, H. Huo et al., “Disease-specific induced pluripotent stem cells,” Cell, vol. 134, no. 5, pp. 877–886, 2008.
- D. Smith, “Commercialization challenges associated with induced pluripotent stem cell-based products,” Regenerative Medicine, vol. 5, no. 4, pp. 593–603, 2010.
- T. Zhao, Z. Zhang, Z. Rong, and Y. Xu, “Immunogenicity of induced pluripotent stem cells,” Nature, vol. 474, no. 7350, pp. 212–215, 2011.
- M. A. Fernandez-Vina, J. P. Klein, M. Haagenson et al., “Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation,” Blood, vol. 121, no. 22, pp. 4603–4610, 2013.
- H. Uchiyama, H. Kayashima, R. Matono et al., “Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome,” Clinical Transplantation, vol. 26, no. 5, pp. E522–E529, 2012.
- T. A. Binkowski, S. R. Marino, and A. Joachimiak, “Predicting HLA class I non-permissive amino acid residues substitutions,” PLoS ONE, vol. 7, no. 8, Article ID e41710, 2012.
- S. O. Ciurea, P. F. Thall, X. Wang et al., “Donor-specific anti-HLAAbs and graft failure in matched unrelated donor hematopoietic stem cell transplantation,” Blood, vol. 118, no. 22, pp. 5957–5964, 2011.
- R. Higgins, D. Lowe, M. Hathaway et al., “Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch,” Transplantation, vol. 92, no. 8, pp. 900–906, 2011.
- C. Susal, D. L. Roelen, G. Fischer et al., “Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients,” Tissue Antigens, vol. 82, no. 2, pp. 83–92, 2013.
- B. L. Davidson and P. B. McCray, “Current prospects for RNA interference-based therapies,” Nature Reviews Genetics, vol. 12, no. 5, pp. 329–340, 2011.
- S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, vol. 411, no. 6836, pp. 494–498, 2001.
- Y. Gu, W. Hou, C. Xu, S. Li, J. W. K. Shih, and N. Xia, “The enhancement of RNAi against HIV in vitro and in vivo using H-2K(k) protein as a sorting method,” Journal of Virological Methods, vol. 182, no. 1-2, pp. 9–17, 2012.
- B. Gillissen, A. Richter, A. Richter et al., “Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent “type I” mode,” Cell Death and Disease, vol. 4, article e643, 2013.
- J. F. Ma, L. Liu, W. J. Yang, L. N. Zang, and Y. M. Xi, “RNAi-mediated knockdown of relaxin decreases in vitro proliferation and invasiveness of osteosarcoma MG-63 cells by inhibition of MMP-9,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 8, pp. 1102–1109, 2013.
- C. Raoul, S. D. Barker, and P. Aebischer, “Viral-based modelling and correction of neurodegenerative diseases by RNA interference,” Gene Therapy, vol. 13, no. 6, pp. 487–495, 2006.
- Y. Hou, L. Xing, S. Fu et al., “Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 247, no. 6, pp. 755–765, 2009.
- J. McCaskill, R. Singhania, M. Burgess et al., “Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA,” Molecular Therapy—Nucleic Acids, vol. 2, article e96, 2013.
- J. Presumey, G. Salzano, G. Courties et al., “PLGA microspheres encapsulating siRNA anti-TNFα: efficient RNAi-mediated treatment of arthritic joints,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, no. 3, pp. 457–464, 2012.
- C. Figueiredo, L. Goudeva, P. A. Horn, B. Eiz-Vesper, R. Blasczyk, and A. Seltsam, “Generation of HLA-deficient platelets from hematopoietic progenitor cells,” Transfusion, vol. 50, no. 8, pp. 1690–1701, 2010.
- C. Figueiredo, A. Seltsam, and R. Blasczyk, “Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery,” Journal of Molecular Medicine, vol. 84, no. 5, pp. 425–437, 2006.
- Y. Jaimes, A. Seltsam, B. Eiz-Vesper, R. Blasczyk, and C. Figueiredo, “Regulation of HLA class II expression prevents allogeneic T-cell responses,” Tissue Antigens, vol. 77, no. 1, pp. 36–44, 2011.
- L. Riolobos, R. K. Hirata, C. J. Turtle et al., “HLA engineering of human pluripotent stem cells,” Molecular Therapy, vol. 21, pp. 1232–1241, 2013.
- R. Dressel, L. Walter, and E. Günther, “Genomic and functional aspects of the rat MHC, the RT1 complex,” Immunological Reviews, vol. 184, pp. 82–95, 2001.
- C. Figueiredo, M. Wittmann, D. Wang et al., “Heat shock protein 70(HSP70) induces cytotoxicity of T-helper cells,” Blood, vol. 113, no. 13, pp. 3008–3016, 2009.
- G. Einecke, B. Sis, J. Reeve et al., “Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure,” The American Journal of Transplantation, vol. 9, no. 11, pp. 2520–2531, 2009.
- D. Ishii, A. D. Schenk, S. Baba, and R. L. Fairchild, “Role of TNFα in early chemokine production and leukocyte infiltration into heart allografts,” The American Journal of Transplantation, vol. 10, no. 1, pp. 59–68, 2010.
- H. Wang, Q. Guan, Z. Lan et al., “Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 2, pp. F276–F283, 2012.
- M. Hummel, S. M. Kurian, S. Lin et al., “Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model,” Transplantation, vol. 87, no. 2, pp. 178–188, 2009.
- C. Ashokkumar, R. Shapiro, H. Tan et al., “Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation,” Transplantation, vol. 92, no. 4, pp. 433–438, 2011.
- E. Kreijveld, H. J. P. M. Koenen, B. van Cranenbroek, E. van Rijssen, I. Joosten, and L. B. Hilbrands, “Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus,” PLoS ONE, vol. 3, no. 7, Article ID e2711, 2008.
- R. Maehr, S. Chen, M. Snitow et al., “Generation of pluripotent stem cells from patients with type 1 diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15768–15773, 2009.
- D. van Hoof, K. A. D'Amour, and M. S. German, “Derivation of insulin-producing cells from human embryonic stem cells,” Stem Cell Research, vol. 3, no. 2-3, pp. 73–87, 2009.
- S. D. Sheridan, K. M. Theriault, S. A. Reis et al., “Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome,” PLoS ONE, vol. 6, no. 10, Article ID e26203, 2011.
- A. Urbach, O. Bar-Nur, G. Q. Daley, and N. Benvenisty, “Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells,” Cell Stem Cell, vol. 6, no. 5, pp. 407–411, 2010.
- N. Kieran, X. Wang, J. Perkins et al., “Combination of peritubular C4d and transplant glomerulopathy predicts late renal allograft failure,” Journal of the American Society of Nephrology, vol. 20, no. 10, pp. 2260–2268, 2009.
- F. G. Cosio, J. M. Gloor, S. Sethi, and M. D. Stegall, “Transplant glomerulopathy,” The American Journal of Transplantation, vol. 8, no. 3, pp. 492–496, 2008.
- N. Kohei, T. Tanabe, S. Horita et al., “Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model,” Kidney International, 2013.
- D. H. Raulet and R. E. Vance, “Self-tolerance of natural killer cells,” Nature Reviews Immunology, vol. 6, no. 7, pp. 520–531, 2006.
- K. Karre, H. G. Ljunggren, G. Piontek, and R. Kiessling, “Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy,” Nature, vol. 319, no. 6055, pp. 675–678, 1986.
- A. A. Wanderer, “Rationale and timeliness for IL-1β-targeted therapy to reduce allogeneic organ injury at procurement and to diminish risk of rejection after transplantation,” Clinical Transplantation, vol. 24, no. 3, pp. 307–311, 2010.
- J. E. Vamvakopoulos, C. J. Taylor, C. Green et al., “Interleukin 1 and chronic rejection: possible genetic links in human heart allografts,” The American Journal of Transplantation, vol. 2, no. 1, pp. 76–83, 2002.
- D. Masopust, V. Vezys, A. L. Marzo, and L. Lefrançois, “Preferential localization of effector memory cells in nonlymphoid tissue,” Science, vol. 291, no. 5512, pp. 2413–2417, 2001.
- Y. M. Ortiz, L. F. Arias, C. M. Alvarez, and L. F. Garcia, “Memory phenotype and polyfunctional T cells in kidney transplant patients,” Transplant Immunology, vol. 28, no. 2-3, pp. 127–137, 2013.